Losmapimod

N/A

Report date: 2024/12/19 11:40:21
NME

Base Information

Drug NameLosmapimod
Drug Alias Name洛吡莫德GSK-AHAB洛玛莫德GW-856553XSB-856553 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitorsMitogen-activated protein kinase 11 inhibitors
TargetsP38 α mitogen-activated protein kinaseMitogen-activated protein kinase 11
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Depressive Disorder, MajorDyslipidemias +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaIND
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Trading Services LtdSanofiFulcrum Therapeutics Inc +[6] 
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsAcute Coronary Syndrome
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Depressive Disorder, MajorDyslipidemias +[10] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG